The Structural Basis of TAM Receptor Oligomerizarion and Co-receptor Interactions
- Institution
- UNIV OF NORTH CAROLINA CHAPEL HILL, NC
- Principal investigator
- Chrystal Starbird
- Funding
- $249K
- Duration
- 2022–2026
Moonbase score
Still being scored
Abstract
TAM receptors are receptor tyrosine kinases with important regulatory roles in cells. These receptors are essential to maintaining cellular homeostasis through the clearance of apoptotic cells and through control of inflammatory and immune responses. Linked to their important regulatory roles, dysregulation of TAM receptors is implicated in numerous disease states including cardiovascular disease, hereditary blindness, autoimmune disorders, chronic inflammation and cancer. While there is growing interest in TAM receptors as therapeutic targets, their multiple roles in homeostatic processes create challenges for developing therapeutic strategies. Understanding TAM receptor activation mechanisms is important for further investigation of the potential development of targeted therapies. While these receptors are commonly believed to be activated through classical receptor-induced dimerization, my preliminary work presents the first in-depth study of the biochemistry and suggests that this simplified view may not be applicable to TAM receptors. Importantly, to fully understand how TAMs are activated, I intend to utilize a combination of structural, biophysical and biochemical approaches to investigate TAM oligomerization and cross-talk with other receptors. These studies will guide the development of informed theories of TAM receptor activation and provide important insights that may be used for the development of new therapeutics in cancer and autoimmune diseases.
LOADING MOONBASE SCORE
Questions for UNIV OF NORTH CAROLINA CHAPEL HILL
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same institution, same topic, scored first.
- NIH · Univ of North Carolina Chapel Hill65
Cortical circuits for the integration of parallel short-latency auditory pathways
Hiroyuki Kato · $469K · 2022–2027
- NIH · Univ of North Carolina Chapel Hill47
Study to establish safety, tolerability and feasibility of LM11A-31 as a neuroprotective agent in aging people living with HIV and neurocognitive impairment on antiretroviral therapy
Rick B Meeker · $638K · 2023–2029
- NIH · Univ of North Carolina Chapel Hill47
Project 1: Cellular requirements for Pol theta
Dale A Ramsden · $428K · 2020–2030